health
February 11, 2026
Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start
The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.
TL;DR
- Novo Nordisk launched the first GLP-1 pill for obesity at the start of 2026 but faces challenges protecting market share.
- The company is suing Hims & Hers for patent infringement related to compounded obesity drugs.
- Novo Nordisk received an FDA warning for allegedly misleading advertising claims.
- The company's 2026 sales and profit outlook was lower than expected, projecting a potential decline, while competitor Eli Lilly projected significant growth.
- Novo Nordisk's stock price has experienced significant volatility due to recent developments.
- Compounding pharmacies selling unapproved copycat versions of Novo Nordisk's drugs are cited as a major reason for slowing sales growth.
- CEO Mike Doustdar is focusing on cracking down on copycats, sustaining demand for the new pill, and developing new treatments.
- Novo Nordisk's Wegovy pill is outperforming the early rollout of existing GLP-1 injections.
- Eli Lilly's Zepbound holds a larger market share in the branded GLP-1 market compared to Novo Nordisk's drugs.
- Novo Nordisk is banking on the Wegovy pill and upcoming next-generation treatments like CagriSema to regain market share.
- The company anticipates Medicare coverage for weight loss treatments, potentially opening up a significant patient opportunity.
- Novo Nordisk believes its specialized therapies approach within obesity and diabetes offers more opportunity than broader diversification.
Continue reading the original article